253 related articles for article (PubMed ID: 25861690)
21. An organ-preserving selective arterial chemotherapy strategy for head and neck cancer.
Kerber CW; Wong WH; Howell SB; Hanchett K; Robbins KT
AJNR Am J Neuroradiol; 1998 May; 19(5):935-41. PubMed ID: 9613516
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer.
Robbins KT; Storniolo AM; Kerber C; Vicario D; Seagren S; Shea M; Hanchett C; Los G; Howell SB
J Clin Oncol; 1994 Oct; 12(10):2113-20. PubMed ID: 7931481
[TBL] [Abstract][Full Text] [Related]
23. Relationship between hematotoxicity and serum albumin level in the treatment of head and neck cancers with concurrent chemoradiotherapy using cisplatin.
Ishizuka M; Fujimoto Y; Itoh Y; Kitagawa K; Sano M; Miyagawa Y; Ando A; Hiramatsu M; Hirasawa N; Ishihara S; Nakashima T; Yamada K
Jpn J Clin Oncol; 2011 Aug; 41(8):973-9. PubMed ID: 21693483
[TBL] [Abstract][Full Text] [Related]
24. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma.
Spring PM; Valentino J; Arnold SM; Sloan D; Kenady D; Kudrimoti M; Haydon RC; Lee C; Given C; Mohiuddin M; Regine WF
Cancer; 2005 Oct; 104(8):1765-71. PubMed ID: 16149090
[TBL] [Abstract][Full Text] [Related]
26. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.
Ang KK; Harris J; Garden AS; Trotti A; Jones CU; Carrascosa L; Cheng JD; Spencer SS; Forastiere A; Weber RS
J Clin Oncol; 2005 May; 23(13):3008-15. PubMed ID: 15860857
[TBL] [Abstract][Full Text] [Related]
27. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer.
Tegeder I; Bräutigam L; Seegel M; Al-Dam A; Turowski B; Geisslinger G; Kovács AF
Clin Pharmacol Ther; 2003 May; 73(5):417-26. PubMed ID: 12732842
[TBL] [Abstract][Full Text] [Related]
28. Indications for superselective intra-arterial cisplatin infusion and concomitant radiotherapy in cases of hypopharyngeal cancer.
Furusawa J; Homma A; Onimaru R; Sakashita T; Yoshida D; Hatakeyama H; Mizumachi T; Kano S; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Auris Nasus Larynx; 2015 Dec; 42(6):443-8. PubMed ID: 25933585
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
30. Ototoxicity in locally advanced head and neck cancer patients treated with induction chemotherapy followed by intermediate or high-dose cisplatin-based chemoradiotherapy.
Driessen CML; Leijendeckers J; Snik A; van der Graaf WTA; de Boer JP; Gelderblom H; Kaanders JHAM; Takes R; van Herpen CML
Head Neck; 2019 Feb; 41(2):488-494. PubMed ID: 30536479
[TBL] [Abstract][Full Text] [Related]
31. Intra-arterial chemoradiotherapy for head and neck cancer.
Homma A; Onimaru R; Matsuura K; Robbins KT; Fujii M
Jpn J Clin Oncol; 2016 Jan; 46(1):4-12. PubMed ID: 26486825
[TBL] [Abstract][Full Text] [Related]
32. Concurrent chemoradiotherapy with low-dose cisplatin plus 5-fluorouracil for the treatment of patients with unresectable head and neck cancer.
Kohno N; Kitahara S; Tamura E; Tanabe T
Oncology; 2002; 63(3):226-31. PubMed ID: 12381901
[TBL] [Abstract][Full Text] [Related]
33. Feasibility of radiotherapy or chemoradiotherapy after taxane-based induction chemotherapy for nonoperated locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Daly-Schveitzer N; Bourhis J; Tao Y
Anticancer Drugs; 2014 Nov; 25(10):1220-6. PubMed ID: 25144345
[TBL] [Abstract][Full Text] [Related]
34. High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma.
de Castro G; Snitcovsky IM; Gebrim EM; Leitão GM; Nadalin W; Ferraz AR; Federico MH
Eur Arch Otorhinolaryngol; 2007 Dec; 264(12):1475-82. PubMed ID: 17643256
[TBL] [Abstract][Full Text] [Related]
35. High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
Perez CA; Wu X; Amsbaugh MJ; Gosain R; Claudino WM; Yusuf M; Roberts T; Jain D; Jenson A; Khanal S; Silverman CI; Tennant P; Bumpous JM; Dunlap NE; Rai SN; Redman RA
Oral Oncol; 2017 Apr; 67():24-28. PubMed ID: 28351577
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
37. Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer.
Heukelom J; Lopez-Yurda M; Balm AJ; Wijers OB; Buter J; Gregor T; Wiggenraad R; de Boer JP; Tan IB; Verheij M; Sonke JJ; Rasch CR
Head Neck; 2016 Apr; 38 Suppl 1():E488-93. PubMed ID: 25728984
[TBL] [Abstract][Full Text] [Related]
38. Promising long-term results with attenuated adverse effects by methotrexate-containing sequential chemoradiation therapy in locally advanced head and neck squamous cell carcinoma.
Tsai TL; Chu PY; Tai SK; Wang YF; Yang MH; Wang LW; Lirng JF; Chang SY
Jpn J Clin Oncol; 2011 Oct; 41(10):1182-93. PubMed ID: 21862506
[TBL] [Abstract][Full Text] [Related]
39. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients.
Schmitt NC; Page BR
Int J Audiol; 2018 Sep; 57(sup4):S49-S54. PubMed ID: 28728452
[TBL] [Abstract][Full Text] [Related]
40. Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer.
Homma A; Sakashita T; Yoshida D; Onimaru R; Tsuchiya K; Suzuki F; Yasuda K; Hatakeyama H; Furusawa J; Mizumachi T; Kano S; Inamura N; Taki S; Shirato H; Fukuda S
Br J Cancer; 2013 Dec; 109(12):2980-6. PubMed ID: 24196792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
